Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00167180
Status:
TERMINATED
Last Update Posted:
2019-07-30
First Post:
2005-09-09
Brief Title:
Post Transplant Donor Lymphocyte Infusion
Sponsor:
Masonic Cancer Center University of Minnesota
Organization:
Masonic Cancer Center University of Minnesota
Study Overview
Official Title:
Use of CyclophosphamideFludarabine to Promote in Vivo Expansion of Donor Lymphocyte Infusions DLI to Enhance Efficacy After Allogeneic Transplant
Status:
TERMINATED
Status Verified Date:
2019-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Accrual Goal Met
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to test the hypothesis that a pre-infusion preparative regimen of cyclophosphamide and fludarabine will improve the effectiveness of DLI in patients with blood cancers
Detailed Description:
When cancer relapses after donor bone marrow transplantation regular dose chemotherapy offers little hope of prolonged survival However there is evidence that lymphocytes can attack cancer cells There is considerable evidence that this immune attack on cancer cells is associated with graft-versus-host disease Although graft-versus-host disease can cause problems this immune reaction may in part be the way that bone marrow transplantation cures cancer In this study we hope that infusion of immune cells from the subjects bone marrow donor plus a chemotherapy regimen of cyclophosphamide and fludarabine will activate the subjects immune system to attack their cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 0401M55207 | OTHER | IRB University of Minnesota | None |
| MT2003-15 | OTHER | None | None |